Sign up Australia
Proactive Investors - Run By Investors For Investors

OBJ's array-back hydrogel technology study delivers promising results

The company's slow release technology may have applications that are beneficial for the ageing population.
Picture of knee guard
92% of participants considered themselves either better or much better following the active patch treatment

OBJ Limited (ASX:OBJ) has received a promising report from Curtin University’s School of Physiotherapy and Exercise Science for a study into slow release technology for the delivery of medications.

The report outlines the results of a double-blind study into the clinical outcomes following a 48-hour administration of a magnetophoresis enhanced transdermal Ibuprofen (5%) patch.

The study sought to demonstrate that OBJ’s array-back hydrogel technology could be used with third-party therapeutic drugs such as ibuprofen.

Applications for ageing population

Ibuprofen and many other similar anti-inflammatory drugs cannot be taken in tablet form for extended periods due to their impact on other organs.

OBJ’s slow-release technology could potentially be an ideal resolution to the problem, and the fact that its target markets could include the ageing population is a positive.

Broad-based results demonstrate pain reduction

There were significant differences between the active patch session and the placebo patch session for all primary outcome measures.

This indicated that participants experienced less pain and improved function during the 48-hour active patch session.

There were also significant improvements across most of the secondary outcome measures with few skin reactions to either placebo or active patches.

Slight skin redness was reported by five participants with the active patches and six participants with the placebo patches, and all associated this with the adhesive tape rather than the gel.

Impressive active knee guard device results

The results were particularly encouraging in relation to OBJ’s active knee guard device containing ibuprofen (5%).

Combined with magnetophoresis, this produced a significantly greater reduction in pain and improvement in function than the placebo device.

There was a significant improvement in participants suffering from movement-related pain.

Twenty-two participants (92%) considered themselves either better or much better following the active patch treatment.

View full OBJ profile View Profile

OBJ Ltd Timeline

September 04 2017
January 25 2016
December 02 2014

Related Articles

Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 06 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
March 01 2018
The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use